Join the members group
Ethical Standards in Health and Life Sciences Group
The Ethical Standards in Health and Life Sciences Group (ESHLSG) is a group of organisations working together to improve how health professionals and the pharmaceutical and life sciences industries work together for the benefit of patients.
The Faculty of Pharmaceutical Medicine is a member of the ESHLSG as we believe that it is critical for us to work with all our partners in other professions, the NHS and in industry. We want to ensure that the systems and processes for health professionals and industry to work together in the UK are fit-for-purpose and effective for the future - and we are working with the ESHLSG to help make this happen.
Every constituent organisation of the ESHLSG, including the Faculty of Pharmaceutical Medicine, is committed to representing the views of its own members at these discussions. We all recognise that we must reflect your view - and those of others including doctors, nurses, physicians, pharmacists, surgeons, managers and industry leaders.
For further information please visit the ESHLSG website.
ESHLSG launch consultation on declaration of payments
The Ethical Standards in Health & Life Sciences Group, of which the Faculty is a member, has launched a consultation of the declaration of payments to HCPs. Read the consultation document here and respond to the survey here.
Faculty President signs letter to the Times - 7.11.12
Richard Tiner (President of the Faculty from November 2009 to November 2012) is one of 19 signatories of a letter to the Times that highlights the work of the healthcare professions and life sciences industry in the campaign for clinical trial transparency
Read the letter here
ESHLSG Medical Education Survey
This consultation is now closed. The results will be published in due course.
The ESHLSG has published a new series of Clinical Trial Transparency Principles and Facts.
This is the first time that leading healthcare professional bodies and senior representatives of the pharmaceutical industry have agreed to a joint approach on this critical issue. This is an important step forward in the on-going move across the entire research community to drive best practice in clinical research reporting.
The ESHLSG Principles document was launched on the 23rd May 2012 at the joint British Medical Journal (BMJ) and Association of the British Pharmaceutical Industry (ABPI) conference: Innovation in research methods and dissemination - ensuring best practice.
Download the document here
Commenting on the document, the former President of the Faculty (from November 2009 to November 2012), Dr Richard Tiner, said:
"The Faculty of Pharmaceutical Medicine welcomes the publication of ‘Clinical Trial Transparency - Principles and Facts' and strongly endorses the guidance contained within. The Faculty believes that only through the open sharing of clinical trial data, whatever the outcome of the trial, will patients feel the true benefits of clinical research. Our own ‘Guiding Principles for Pharmaceutical Physicians' document (referenced therein) also promotes this philosophy."
Launch of FPM endorsed document ‘Guidance on collaboration between healthcare professionals and the pharmaceutical industry'
The 29th March saw the release of an important document designed to promote and clarify the relationships between the pharmaceutical industry and healthcare professionals. It contains a number of recommendations for open and positive ‘standards of engagement' and ways to encourage collaboration, for the benefit of patients and the public.
Commenting on the document, Dr Richard Tiner, President of the Faculty of Pharmaceutical Medicine (from November 2009 to November 2012), said:
"As the standard-setting body for doctors working in the pharmaceutical industry, and a link between these two communities, the Faculty of Pharmaceutical Medicine welcomes the release of this guidance document. We believe that the principles within it herald a new era of collaborative working that will encourage innovation in science and medical practice in the UK for the benefit of patients. The Faculty is particularly pleased that the issue of adverse event reporting, point 9, has been highlighted, as the utilisation of the yellow-card scheme by healthcare professionals and patients is vital in developing safe and effective medicines."